Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bismuth Potassium Citrate,Metronidazole,Tetracycline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Bismuth subcitrate potassium and antibacterial agents (metronidazole and tetracycline hydrochloride) capsules in combination are indicated for treating H.pylori infection and duodenal ulcer disease to eradicate H. pylori.
Brand Name : Pylera-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 10, 2023
Lead Product(s) : Bismuth Potassium Citrate,Metronidazole,Tetracycline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Bismuth Potassium Citrate,Metronidazole,Tetracycline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : AbbVie Inc
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Pylera®, a 3-in-1 combination of antimicrobial products, is indicated for the treatment of patients with Helicobacter pylori infection suffering from gastro-duodenal ulcer disease.
Brand Name : Pylera
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 05, 2022
Lead Product(s) : Bismuth Potassium Citrate,Metronidazole,Tetracycline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : AbbVie Inc
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?